Valirx (VAL)


VAL Share PerformanceMore

52 week high7.2400 29/11/16
52 week low0.9000 15/11/17
52 week change -5.7000 (-86.04%)
4 week volume37,384,576 22/10/17

Media for (VAL)

Presenter: Suzanne Dilly
Presenter: Oliver de Giorgio-Miller

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Yorkville CLN Conversion

RNS Number: 6282W ValiRx PLC 15 November 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Loan Note Conversion and Issue of Equity London, UK ., 15 November 2017: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines ...

ValiRx obtains new US patent allowance

ValiRx said its joint venture with Tangent Reprofiling has obtained a new US patent allowance. The clinical stage therapeu...

Notification of US Patent Allowance

RNS Number: 2470T ValiRx PLC 11 October 2017 VALIRX PLC ("ValiRx", the "Company" or the "Group") NOTIFICATION OF US PATENT ALLOWANCE FOR THERAPEUTIC COMPOUND, VAL401 London, UK ., 11 October 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to report that ValiSeek Limited ("ValiSeek"), the join...

Holding(s) in Company

RNS Number: 7448S ValiRx PLC 05 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: ValiRx PLC 1b. Please ind...

Total Voting Rights

RNS Number: 1466S ValiRx PLC 02 October 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Total Voting Rights The Company announces that the total number of ordinary shares of 0.1 pence each of the Company at the date of this notice is 203,958,937 with each share carrying the right to one vote. There are no shares held in Treasury. The total num...

ValiRx cancer treatment JV progressing well

ValiRx, the clinical stage biotechnology company, said its joint venture with Tangent Reprofiling is progressing well. ValiSe...

ValiSeek Clinical Development Update

RNS Number: 0182S ValiRx PLC 28 September 2017 ValiRx Plc ("ValiRx" or the "Company") VALISEEK CLINICAL DEVELOPMENT UPDATE "First Verified Data Release from VAL401 Phase II Clinical Trial" London, UK ., 28 September 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to provide a positive development update...

ValiRx - Valiseek Clinical Development Update

Fundamental DataMore

Dividend yield0 %

Latest discussion posts More

Users' HoldingsMore

Users who hold Valirx also hold..

Codes & Symbols


Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account